Recent Updates
Recently added Catalysts
KRYS Positive Sentiment Score: 70/100

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

Monday, October 30, 2023 2 min read
Key Takeaway: Krystal Biotech, Inc. is set to report its third quarter financial results on November 6, 2023, before the U.S. markets open. Following the release, the company will hold an investor conference call at 8:30 am ET to provide insights into its financial performance and business developments. Krystal Biotech is known for its groundbreaking gene therapy, VYJUVEK®, and is advancing a diverse pipeline targeting several medical fields.

Market Sentiment Analysis

POSITIVE FACTORS

  • Krystal Biotech is reporting its financial results, indicating active business operations.
  • The upcoming investor conference call suggests transparency and engagement with stakeholders.
  • The company has a robust pipeline in various disease areas, indicating potential for future growth.

Full Press Release Details

PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs, will report its third quarter 2023 financial results on Monday, November 6, 2023, prior to the open of U.S. markets. Subsequently, at 8:30 am ET, the Company will host an investor conference call to discuss the financial results and provide a business update.
Investor Conference Call
The Company will host an investor conference call on Monday, November 6, 2023 at 8:30 am ET. To access the live conference call, please pre-register at: https://www.netroadshow.com/events/login?show=15609a11&confId=57029.
For those unable to listen to the live conference call, a replay will be available for 30-days on the Investors section of the Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK® is the Company’s first commercial product, the first-ever redosable gene therapy, and the only medicine approved by the FDA for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines in respiratory, oncology, dermatology, ophthalmology, and aesthetics. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn and Twitter.
Investors and Media:
mdodge@krystalbio.com

Frequently Asked Questions

When will Krystal Biotech report its Q3 2023 financial results?

Krystal Biotech will report its Q3 2023 financial results on November 6, 2023.

What time is the investor conference call on November 6?

The investor conference call will start at 8:30 am ET on November 6, 2023.

How can I access the investor conference call?

To access the call, please pre-register at the specified netroadshow link.

Is there a replay of the conference call available?

Yes, a replay will be available for 30 days on the Company’s website.

What is VYJUVEK®?

VYJUVEK® is Krystal Biotech's first product, approved for dystrophic epidermolysis bullosa.

Tags: KRYS Viatris Investor Conferences Healthcare Krystal Biotech financial results gene therapy biotechnology
Last updated: Oct 30, 2023